

# Vinay Prasad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5320299/publications.pdf>

Version: 2024-02-01

331  
papers

9,153  
citations

66343

42  
h-index

51608

86  
g-index

334  
all docs

334  
docs citations

334  
times ranked

12197  
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistent reservations against the premedical and medical curriculum. Perspectives on Medical Education, 2022, 2, 335-339.	3.5	5
2	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evidence-Based Medicine, 2022, 27, 46-54.	3.5	16
3	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2022, 5, 98-99.	0.3	0
4	When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100. BMJ Evidence-Based Medicine, 2022, 27, 151-152.	3.5	1
5	An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals. Digestive Diseases and Sciences, 2022, 67, 2011-2018.	2.3	2
6	Idecabtagene vicleucel: questions regarding the appropriate role and cost. British Journal of Haematology, 2022, 196, .	2.5	3
7	Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. Cancer, 2022, 128, 311-316.	4.1	9
8	Colorectal cancer screening at a younger age: pitfalls in the model-based recommendation of the USPSTF. BMJ Evidence-Based Medicine, 2022, 27, 206-208.	3.5	1
9	Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm. Translational Oncology, 2022, 15, 101248.	3.7	10
10	Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. British Journal of Haematology, 2022, 196, 1274-1277.	2.5	9
11	Eliceptant in metastatic breast cancer: Is the "standard of care" meeting standard requirements?. Translational Oncology, 2022, 15, 101273.	3.7	0
12	Artificial intelligence and magnetic resonance imaging may not make cancer screening better. Journal of Cancer Policy, 2022, 31, 100314.	1.4	0
13	The frequency of assessment of progression in randomized oncology clinical trials. Cancer Reports, 2022, 5, e1527.	1.4	4
14	Overall survival for oncology drugs approved for genomic indications. European Journal of Cancer, 2022, 160, 175-179.	2.8	6
15	A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers. Journal of Cancer Policy, 2022, 31, 100319.	1.4	1
16	An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC). BMC Cancer, 2022, 22, 70.	2.6	2
17	Retrospective comparative effectiveness research: will changing the analytical methods change the results?. International Journal of Cancer, 2022, , .	5.1	4
18	Reporting of Physicians' or Investigators' Choice of Treatment in Oncology Randomized Clinical Trials. JAMA Network Open, 2022, 5, e2144770.	5.9	4

#	ARTICLE	IF	CITATIONS
19	The accelerated approval pathway in oncology: Balancing the benefits and potential harms.. Journal of Cancer Policy, 2022, 32, 100323.	1.4	2
20	Quality of biomarker defined subgroups in <scp>FDA</scp> approvals of <scp>PD</scp> /<scp>PD</scp> inhibitors 2014 to 2020. International Journal of Cancer, 2022, 150, 1905-1910.	5.1	3
21	Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TVâ€™s The Resident. European Journal of Emergency Medicine, 2022, 29, 142-143.	1.1	1
22	The Kardashian Index: a study of researchers' opinions on twitter 2014â€“2021. Scientometrics, 2022, 127, 1923-1930.	3.0	2
23	Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. European Journal of Cancer, 2022, , .	2.8	4
24	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. European Journal of Cancer, 2022, 164, 95-104.	2.8	0
25	Post-protocol therapy and informative censoring in the CANDOR study. Lancet Oncology, The, 2022, 23, e97.	10.7	1
26	Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. JAMA Network Open, 2022, 5, e222265.	5.9	26
27	High US drug prices have global implications. BMJ, The, 2022, 376, o693.	6.0	7
28	Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Antiâ€“PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial. Journal of Clinical Oncology, 2022, 40, 1596-1597.	1.6	4
29	Targeted therapy in lung cancer: Are we closing the gap in years of life lost?. Cancer Medicine, 2022, 11, 3417-3424.	2.8	7
30	The use and meaning of the parachute metaphor in biomedicine: a citation analysis of a systematic review and a randomized trial of the parachute for freefall. Journal of Comparative Effectiveness Research, 2022, 11, 383-390.	1.4	1
31	The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.. Translational Oncology, 2022, 18, 101374.	3.7	25
32	Characteristics of oncology podcasts: Attitudes, speakers, conflicts. Journal of Cancer Policy, 2022, 32, 100329.	1.4	6
33	Tebentafusp in first-line melanoma trials: An outperforming outlier. Translational Oncology, 2022, 20, 101408.	3.7	11
34	Where are randomized trials necessary: Are smoking and parachutes good counterexamples?. European Journal of Clinical Investigation, 2022, 52, e13730.	3.4	4
35	The Effect of Hospital Visitor Policies on Patients, Their Visitors, and Health Care Providers During the COVID-19 Pandemic: A Systematic Review. American Journal of Medicine, 2022, 135, 1158-1167.e3.	1.5	22
36	Accelerated approval requirements for lurbinectedin. Lancet Oncology, The, 2022, 23, e206.	10.7	1

#	ARTICLE	IF	CITATIONS
37	Multiplicity: When many analytic plans are applied or many redundant studies are run, false-positive results are ensured. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13802.	3.4	1
38	FDA precedents in drug approvals: Contradiction in promoting more treatment options. <i>European Journal of Cancer</i> , 2022, 169, 123-125.	2.8	0
39	Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials. <i>JAMA Network Open</i> , 2022, 5, e2212327.	5.9	4
40	General payments from Biogen to U.S. physicians between 2015 and 2020. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 3035-3038.	2.6	0
41	Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022. <i>JAMA Network Open</i> , 2022, 5, e2216058.	5.9	9
42	Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?. <i>JCO Oncology Practice</i> , 2022, 18, e1164-e1169.	2.9	13
43	Common misconceptions of randomized controlled trials in oncology. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	3.4	1
44	Drug Approvals in Hepatocellular Carcinoma—Filling the Nonexistent Gap?. <i>JAMA Oncology</i> , 2021, 7, 173.	7.1	3
45	The response rate of alternative treatments for drugs approved on the basis of response rate. <i>International Journal of Cancer</i> , 2021, 148, 713-722.	5.1	8
46	Persistent challenges with treating multiple myeloma early. <i>Blood</i> , 2021, 137, 456-458.	1.4	17
47	Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 7-8.	27.6	7
48	Considering benefit and risk before routinely recommending SpaceOAR. <i>Lancet Oncology</i> , The, 2021, 22, 11-13.	10.7	23
49	Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00558.	2.9	4
50	Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018. <i>JAMA Internal Medicine</i> , 2021, 181, 162.	5.1	27
51	Approval and Coverage of Cancer Drugs in England, Canada, and the US. <i>JAMA Internal Medicine</i> , 2021, 181, 509.	5.1	7
52	Pembrolizumab for Non-muscle-Invasive Bladder Cancer—A Costly Therapy in Search of Evidence. <i>JAMA Oncology</i> , 2021, 7, 501.	7.1	10
53	Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. <i>Lancet Haematology</i> , the, 2021, 8, e299-e304.	4.6	10
54	Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100149.	1.1	3

#	ARTICLE	IF	CITATIONS
55	Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions?. <i>Journal of General Internal Medicine</i> , 2021, 36, 3202-3204.	2.6	6
56	The regulatory saga of fedratinib. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522110160.	0.9	1
57	Assessment of New Molecular Entities Approved for Cancer Treatment in 2020. <i>JAMA Network Open</i> , 2021, 4, e2112558.	5.9	3
58	N of 1 Data Sharing: The Impact of Data Sharing within the Hematologyâ€“Oncology Drug Products Division of the US FDA. <i>Trends in Cancer</i> , 2021, 7, 395-399.	7.4	1
59	Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. <i>JAMA Oncology</i> , 2021, 7, 728.	7.1	94
60	Multiple myeloma triplet therapies: baseline characteristics and control groups. <i>Lancet, The</i> , 2021, 397, 1620-1621.	13.7	1
61	Accurate accounting of caplacizumab cost effectiveness. <i>Lancet Haematology,the</i> , 2021, 8, e315.	4.6	3
62	Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13580.	3.4	7
63	Industry payments to US physicians for cancer therapeutics: An analysis of the 2016â€“2018 open payments datasets. <i>Journal of Cancer Policy</i> , 2021, 28, 100283.	1.4	5
64	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. <i>European Urology</i> , 2021, 79, 710-712.	1.9	9
65	The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. <i>Leukemia and Lymphoma</i> , 2021, 62, 2793-2795.	1.3	10
66	The Oncologic Drugs Advisory Committee Votes of April 2021â€“Implications for the Fate of Accelerated Approval. <i>JAMA Oncology</i> , 2021, 7, 1607-1609.	7.1	14
67	Old-fashioned Intelligence Will Always Be Needed in Medicine. <i>European Urology Focus</i> , 2021, 7, 685-686.	3.1	0
68	The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years. <i>JAMA Oncology</i> , 2021, 7, 1569.	7.1	11
69	Has the Current Oncology Value Paradigm Forgotten Patientsâ€™ Time?. <i>JAMA Oncology</i> , 2021, 7, 1757.	7.1	17
70	After <sc>COVID</sc>â€™19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems. <i>International Journal of Cancer</i> , 2021, 149, 1723-1724.	5.1	1
71	The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009â€“2018. <i>BMC Cancer</i> , 2021, 21, 889.	2.6	5
72	Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. <i>European Journal of Cancer</i> , 2021, 155, 163-167.	2.8	7

#	ARTICLE	IF	CITATIONS
73	Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature. <i>JAMA Internal Medicine</i> , 2021, , .	5.1	5
74	New drugs and options can enhance patient outcomes: But can they also erode them?. <i>European Journal of Cancer</i> , 2021, 154, 1-3.	2.8	1
75	Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124728.	5.9	4
76	The FDA's latest move to expand eligibility for oncology trials "a double-edged sword?. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 745-746.	27.6	1
77	Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COVS vaccination. <i>Frontiers of Medicine</i> , 2021, 15, 938-941.	3.4	2
78	The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2305-2308.	3.0	0
79	Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 156, 164-174.	2.8	9
80	How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond. <i>European Journal of Cancer</i> , 2021, 157, 68-70.	2.8	7
81	Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 80-86.	5.0	11
82	Multi-cancer screening tests: communicating about risks should be prioritized.. <i>American Journal of Medicine</i> , 2021, , .	1.5	3
83	An Empirical Analysis of Precision Previvorship: Are Familial and High-Risk Cancer Preventive Programs Evidence-Based?. <i>American Journal of Medicine</i> , 2021, , .	1.5	0
84	Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020. <i>Journal of Cancer Policy</i> , 2021, 30, 100311.	1.4	2
85	Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020. <i>JAMA Network Open</i> , 2021, 4, e2135123.	5.9	20
86	Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action. <i>JAMA Network Open</i> , 2021, 4, e2138793.	5.9	54
87	Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington. <i>JAMA Internal Medicine</i> , 2020, 180, 329.	5.1	4
88	A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 19-22.	2.3	1
89	The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. <i>JAMA Internal Medicine</i> , 2020, 180, 315.	5.1	5
90	Examining the Use of Real-World Evidence in the Regulatory Process. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 843-852.	4.7	99

#	ARTICLE	IF	CITATIONS
91	Medical reversals in low- and middle-income countries. <i>International Journal of Health Planning and Management</i> , 2020, 35, 631-638.	1.7	1
92	Concerning survival signal for eltrombopag in MDS/AML. <i>Leukemia and Lymphoma</i> , 2020, 61, 1002-1003.	1.3	0
93	Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?. <i>European Journal of Cancer</i> , 2020, 139, 20-26.	2.8	11
94	Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2020, 96, 106420.	0.8	3
95	Response to Comment on "Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?". <i>Pharmacoeconomics</i> , 2020, 38, 895-896.	3.3	1
96	Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. <i>Future Science OA</i> , 2020, 6, FSO600.	1.9	9
97	Drug repurposing in oncology " Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e544.	10.7	1
98	Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR). <i>Mayo Clinic Proceedings</i> , 2020, 95, 889-910.	3.0	1
99	Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. <i>Lancet Oncology</i> , The, 2020, 21, 1134-1136.	10.7	22
100	Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations?. <i>JAMA Network Open</i> , 2020, 3, e2012119.	5.9	17
101	Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing. <i>European Journal of Cancer</i> , 2020, 141, 152-161.	2.8	13
102	Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?. <i>Cancer</i> , 2020, 126, 4087-4088.	4.1	8
103	Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. <i>JAMA Internal Medicine</i> , 2020, 180, 1108.	5.1	57
104	Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. <i>JAMA Network Open</i> , 2020, 3, e200423.	5.9	148
105	News Coverage of the American Cancer Society's Update to Colorectal Cancer Screening Guidelines. <i>Mayo Clinic Proceedings</i> , 2020, 95, 617-618.	3.0	5
106	Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e200363.	5.9	49
107	Shifting, overlapping and expanding use of "precision oncology" terminology: a retrospective literature analysis. <i>BMJ Open</i> , 2020, 10, e036357.	1.9	8
108	A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer. <i>Trends in Cancer</i> , 2020, 6, 736-738.	7.4	3

#	ARTICLE	IF	CITATIONS
109	US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. <i>Cancer</i> , 2020, 126, 4270-4272.	4.1	3
110	Medical Reversals in Family Practice: A Review. <i>Current Therapeutic Research</i> , 2020, 92, 100579.	1.2	1
111	Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions. <i>Mayo Clinic Proceedings</i> , 2020, 95, 424-426.	3.0	4
112	Statistical significance and clinical evidence – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e119.	10.7	1
113	Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?. <i>Pharmacoeconomics</i> , 2020, 38, 729-731.	3.3	2
114	Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non-Small Cell Lung Cancers. <i>JAMA Network Open</i> , 2020, 3, e202488.	5.9	17
115	Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. <i>JAMA Internal Medicine</i> , 2020, 180, 797.	5.1	8
116	FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019. <i>JAMA Internal Medicine</i> , 2020, 180, 912.	5.1	61
117	The evidence landscape in precision medicine. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	16
118	Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 428-433.	4.9	9
119	An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 161-167.	4.9	1
120	The Necessity of Sham Controls. <i>American Journal of Medicine</i> , 2019, 132, e29-e30.	1.5	10
121	A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2303-2311.	2.5	7
122	A reality check of the accelerated approval of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 656-658.	27.6	29
123	A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. <i>ELife</i> , 2019, 8, .	6.0	71
124	Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma. <i>Journal of Cancer Policy</i> , 2019, 21, 100189.	1.4	10
125	Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?. <i>Mayo Clinic Proceedings</i> , 2019, 94, 951-956.	3.0	3
126	An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. <i>JAMA Internal Medicine</i> , 2019, 179, 915.	5.1	107

#	ARTICLE	IF	CITATIONS
127	Real-world Evidence—What Does It Really Mean?. JAMA Oncology, 2019, 5, 781.	7.1	43
128	Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. JAMA Network Open, 2019, 2, e193981.	5.9	7
129	Case Reports in the Age of Twitter. American Journal of Medicine, 2019, 132, e725-e726.	1.5	13
130	Should Evidence Come with an Expiration Date?. Journal of General Internal Medicine, 2019, 34, 1356-1357.	2.6	7
131	Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Network Open, 2019, 2, e192535.	5.9	842
132	Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. JAMA Oncology, 2019, 5, 887.	7.1	73
133	Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method. Cmaj, 2019, 191, E272-E273.	2.0	2
134	Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. JAMA Internal Medicine, 2019, 179, 642.	5.1	76
135	Testing Healthcare Workers for Latent Tuberculosis: Is It Evidence Based, Bio-Plausible, Both, Or Neither?. American Journal of Medicine, 2019, 132, 1260-1261.	1.5	5
136	Registration studies — when should patients be deemed ineligible for aggressive therapy?. Nature Reviews Clinical Oncology, 2019, 16, 333-334.	27.6	2
137	Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. JAMA Network Open, 2019, 2, e1916091.	5.9	11
138	Multiplicity in oncology randomised controlled trials: a threat to medical evidence?. Lancet Oncology, The, 2019, 20, 1638-1640.	10.7	9
139	Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours. Current Oncology, 2019, 26, 791-792.	2.2	3
140	The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another. American Journal of Medicine, 2019, 132, e509-e511.	1.5	4
141	Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs. American Journal of Medicine, 2019, 132, 718-721.	1.5	3
142	A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. European Journal of Cancer, 2019, 106, 196-211.	2.8	127
143	Cancer screening: A modest proposal for prevention. Cleveland Clinic Journal of Medicine, 2019, 86, 157-160.	1.3	3
144	PFO closure for secondary stroke prevention: is the discussion closed?. Journal of Thrombosis and Thrombolysis, 2018, 46, 74-76.	2.1	2

#	ARTICLE	IF	CITATIONS
145	Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. JAMA Oncology, 2018, 4, 1093.	7.1	274
146	Assessing Pharmaceutical Research and Development Costs—Reply. JAMA Internal Medicine, 2018, 178, 588.	5.1	6
147	The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study. CMAJ Open, 2018, 6, E57-E62.	2.4	12
148	Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. CMAJ Open, 2018, 6, E31-E38.	2.4	27
149	Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. JAMA Oncology, 2018, 4, 157.	7.1	114
150	Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy?. Journal of General Internal Medicine, 2018, 33, 3-5.	2.6	9
151	Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ: British Medical Journal, 2018, 360, k668.	2.3	28
152	Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. JAMA Oncology, 2018, 4, 994.	7.1	93
153	Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration. JAMA Internal Medicine, 2018, 178, 743.	5.1	9
154	Tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers. Nature Reviews Clinical Oncology, 2018, 15, 11-12.	27.6	177
155	Overall Survival vs Disease-Specific Survival—Reply. JAMA Oncology, 2018, 4, 586.	7.1	5
156	Nusinersen for Spinal Muscular Atrophy. JAMA Pediatrics, 2018, 172, 123.	6.2	30
157	Unanticipated Outcomes: A Medical Memoir—A Book Review. JAMA Internal Medicine, 2018, 178, 11.	5.1	4
158	Meaningful and Accurate Disclosure of Conflict of Interest at the ASTRO National Meeting: A Need for Reassessment of Current Policies. Journal of Oncology Practice, 2018, 14, e692-e698.	2.5	7
159	Moving Precision Oncology Forward Amid Myths and Misconceptions—Reply. JAMA Oncology, 2018, 4, 1790.	7.1	0
160	Addendum: Low-value approvals and high prices might incentivize ineffective drug development. Nature Reviews Clinical Oncology, 2018, 15, 787-787.	27.6	0
161	Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?. Cardiovascular Drugs and Therapy, 2018, 32, 633-635.	2.6	10
162	Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?. European Journal of Cancer, 2018, 104, 252-253.	2.8	5

#	ARTICLE	IF	CITATIONS
163	Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapyâ€”Reply. JAMA Oncology, 2018, 4, 1785.	7.1	10
164	Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. BMJ: British Medical Journal, 2018, 362, k3783.	2.3	7
165	Inconsistent Reporting of Potential Conflicts of Interest. JAMA Oncology, 2018, 4, 1439.	7.1	2
166	Eliminating MRD â€” FDA approval of blinatumomab for B-ALL in complete remission. Nature Reviews Clinical Oncology, 2018, 15, 727-728.	27.6	10
167	Improving observational studies in the era of big data. Lancet, The, 2018, 392, 716-717.	13.7	29
168	Choice of control group in randomised trials of cancer medicine: are we testing trivialities?. Lancet Oncology, The, 2018, 19, 1150-1152.	10.7	13
169	Direct-to-Consumer Genetic Testing. JAMA - Journal of the American Medical Association, 2018, 319, 2377.	7.4	52
170	Low-value approvals and high prices might incentivize ineffective drug development. Nature Reviews Clinical Oncology, 2018, 15, 399-400.	27.6	17
171	A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. European Journal of Cancer, 2018, 101, 143-151.	2.8	15
172	Inconsistent Reporting of Potential Conflicts of Interest. JAMA Pediatrics, 2018, 172, 886.	6.2	0
173	Why is research in early-stage cancer research so low?. Journal of Cancer Policy, 2018, 17, 4-8.	1.4	2
174	Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studiesâ€”Reply. JAMA Oncology, 2018, 4, 1300.	7.1	1
175	Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004886.	2.2	3
176	Cost-effectiveness of Nusinersen for Spinal Muscular Atrophyâ€”Reply. JAMA Pediatrics, 2018, 172, 701.	6.2	2
177	The US Food and Drug Administrationâ€™s use of pathologic complete response as regulatory endpoint: Did it pay off?. Journal of Cancer Policy, 2018, 16, 49-51.	1.4	1
178	Inconsistent Reporting of Potential Conflicts of Interest. JAMA Internal Medicine, 2018, 178, 1424.	5.1	1
179	A pooled analysis of published, basket trials in cancer medicine. European Journal of Cancer, 2018, 101, 244-250.	2.8	19
180	If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis. Journal of General Internal Medicine, 2018, 33, 1213-1214.	2.6	1

#	ARTICLE	IF	CITATIONS
181	Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter. JAMA Internal Medicine, 2017, 177, 425.	5.1	44
182	Drugs that lack single-agent activity: are they worth pursuing in combination?. Nature Reviews Clinical Oncology, 2017, 14, 193-194.	27.6	25
183	What constitutes an "unmet medical need" in oncology? An empirical evaluation of author usage in the biomedical literature. Seminars in Oncology, 2017, 44, 8-12.	2.2	14
184	Pharmaceutical Marketing for Rare Diseases. JAMA - Journal of the American Medical Association, 2017, 317, 2479.	7.4	12
185	Combining drugs and extending treatment " a PFS end point is not sufficient. Nature Reviews Clinical Oncology, 2017, 14, 521-522.	27.6	16
186	How the USPSTF's Mammographic Screening Guidelines Should Be Interpreted. American Journal of Medicine, 2017, 130, 769-770.	1.5	1
187	The high price of anticancer drugs: origins, implications, barriers, solutions. Nature Reviews Clinical Oncology, 2017, 14, 381-390.	27.6	289
188	Use of word "unprecedented" in the media coverage of cancer drugs: Do "unprecedented" drugs live up to the hype?. Journal of Cancer Policy, 2017, 14, 16-20.	1.4	3
189	A further strategy to combat the high price of anticancer drugs. Nature Reviews Clinical Oncology, 2017, 14, 629-629.	27.6	2
190	Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Internal Medicine, 2017, 177, 1569.	5.1	333
191	Conflicts of interest in Twitter. Lancet Haematology, the, 2017, 4, e408-e409.	4.6	20
192	Me-too drugs with limited benefits " the tale of regorafenib for HCC. Nature Reviews Clinical Oncology, 2017, 14, 653-654.	27.6	17
193	Overestimating the Benefit of Cancer Drugs. JAMA Oncology, 2017, 3, 1737.	7.1	8
194	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Seminars in Oncology, 2017, 44, 132-135.	2.2	90
195	Is "Do Everything! Always Appropriate?" Reply. JAMA Oncology, 2017, 3, 1588.	7.1	2
196	Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals. Blood Cancer Journal, 2017, 7, 637.	6.2	5
197	Limitations Concerning the Association of Physician Sex and Patient Outcomes. JAMA Internal Medicine, 2017, 177, 1058.	5.1	3
198	Pembrolizumab as first-line therapy in programmed death ligand 1 "positive advanced lung cancer: Is it as effective as we think it is?. Cancer, 2017, 123, 3872-3874.	4.1	4

#	ARTICLE	IF	CITATIONS
199	The Rising Price of Cancer Drugsâ€™ A New Old Problem?. JAMA Oncology, 2017, 3, 277.	7.1	21
200	Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World. JAMA Oncology, 2017, 3, 889.	7.1	28
201	Taking Care of Our Friends and Neighbors. JAMA Oncology, 2017, 3, 16.	7.1	3
202	Clinically meaningful benefit: real world use compared against the American and European guidelines. Blood Cancer Journal, 2017, 7, 645.	6.2	5
203	Do cancer drugs improve survival or quality of life?. BMJ: British Medical Journal, 2017, 359, j4528.	2.3	51
204	Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. BMC Medicine, 2017, 15, 134.	5.5	169
205	Negative trials in ovarian cancer: is there such a thing as too much optimism?. Ecancermedicalsience, 2016, 10, ed58.	1.1	7
206	Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. European Journal of Heart Failure, 2016, 18, 128-132.	7.1	9
207	Industry Funding of Cancer Patient Advocacy Organizations. Mayo Clinic Proceedings, 2016, 91, 1668-1670.	3.0	26
208	Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clinic Proceedings, 2016, 91, 713-725.	3.0	91
209	Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?. Medical Hypotheses, 2016, 93, 71-73.	1.5	3
210	ASCO Plenary Sessions: impact, legacy, future. Seminars in Oncology, 2016, 43, 321-326.	2.2	3
211	Reply to Dr. Leon: true but unrelated. Journal of Clinical Epidemiology, 2016, 75, 127.	5.0	1
212	Balancing Accelerated Approval for Drugs With Accelerated Withdrawalâ€™Reply. JAMA Internal Medicine, 2016, 176, 567.	5.1	0
213	Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. JAMA - Journal of the American Medical Association, 2016, 316, 271.	7.4	26
214	Same Data; Different Interpretations. Journal of Clinical Oncology, 2016, 34, 3729-3732.	1.6	6
215	Perspective: The precision-oncology illusion. Nature, 2016, 537, S63-S63.	27.8	236
216	Precision medicine in diffuse large B-cell lymphoma: Hype or hope?. European Journal of Cancer, 2016, 68, 22-26.	2.8	1

#	ARTICLE	IF	CITATIONS
217	Precision medicine in acute myeloid leukemia: Hope, hype or both?. Leukemia Research, 2016, 48, 73-77.	0.8	12
218	Effect of the American Society of Clinical Oncology's Conflict of Interest Policy on Information Overload. JAMA Oncology, 2016, 2, 1653.	7.1	19
219	Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off?. Journal of General Internal Medicine, 2016, 31, 1367-1368.	2.6	4
220	Future jobs of FDA's haematology-oncology reviewers. BMJ, The, 2016, 354, i5055.	6.0	20
221	Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. Oncologist, 2016, 21, 1031-1032.	3.7	6
222	Blood-Based Screening for Colon Cancer. JAMA - Journal of the American Medical Association, 2016, 315, 2519.	7.4	31
223	The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem. Mayo Clinic Proceedings, 2016, 91, 707-712.	3.0	21
224	Translation failure and medical reversal: Two sides to the same coin. European Journal of Cancer, 2016, 52, 197-200.	2.8	8
225	The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival?. European Journal of Cancer, 2016, 54, 159-162.	2.8	2
226	Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. Oncologist, 2016, 21, 261-268.	3.7	30
227	Precision oncology: origins, optimism, and potential. Lancet Oncology, The, 2016, 17, e81-e86.	10.7	190
228	In Reply"Is There a Need for "Bias Police" in Industry-Sponsored Research?. Mayo Clinic Proceedings, 2016, 91, 121.	3.0	0
229	Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration. JAMA Internal Medicine, 2016, 176, 389.	5.1	29
230	Application of Medicare's New Technology Add-on Payment Program for Blinatumomab. JAMA Oncology, 2016, 2, 165.	7.1	3
231	Why cancer screening has never been shown to "save lives" and what we can do about it. BMJ, The, 2016, 352, h6080.	6.0	98
232	The Use of Superlatives in Cancer Research. JAMA Oncology, 2016, 2, 139.	7.1	57
233	Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. European Journal of Cancer, 2015, 51, 2718-2723.	2.8	5
234	Roflumilast in COPD: Response. Chest, 2015, 148, e31-e32.	0.8	0

#	ARTICLE	IF	CITATIONS
235	How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. <i>Blood</i> , 2015, 126, 1860-1861.	1.4	16
236	Authorship Inflation in Medical Publications. <i>Inquiry (United States)</i> , 2015, 52, 004695801559831.	0.9	46
237	Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. <i>Oncologist</i> , 2015, 20, 1344-1346.	3.7	0
238	Emphasizing unique strengths and eliminating redundancy for research in low-income and middle-income countries: Lessons from a South American country. <i>Cancer</i> , 2015, 121, 2668-2670.	4.1	1
239	Five Years of Cancer Drug Approvals. <i>JAMA Oncology</i> , 2015, 1, 539.	7.1	271
240	Mortality and Treatment Patterns Among Patients Hospitalized With Acute Cardiovascular Conditions During Dates of National Cardiology Meetings. <i>JAMA Internal Medicine</i> , 2015, 175, 237.	5.1	56
241	Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?. <i>Cmaj</i> , 2015, 187, E276-E278.	2.0	9
242	Use of the Word "Cure" in the Oncology Literature. <i>American Journal of Hospice and Palliative Medicine</i> , 2015, 32, 477-483.	1.4	12
243	Do we need randomised trials for rare cancers?. <i>European Journal of Cancer</i> , 2015, 51, 1355-1357.	2.8	9
244	Non-inferiority trials: why oncologists must remain wary. <i>Lancet Oncology</i> , The, 2015, 16, 364-366.	10.7	19
245	Colorectal Cancer Survival Gains and Novel Treatment Regimens. <i>JAMA Oncology</i> , 2015, 1, 787.	7.1	75
246	The Strength of Association Between Surrogate End Points and Survival in Oncology. <i>JAMA Internal Medicine</i> , 2015, 175, 1389.	5.1	287
247	The role of censoring on progression free survival: Oncologist discretion advised. <i>European Journal of Cancer</i> , 2015, 51, 2269-2271.	2.8	18
248	Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival. <i>JAMA Internal Medicine</i> , 2015, 175, 1992.	5.1	287
249	Pricing and Value of Cancer Drugs"Reply. <i>JAMA Oncology</i> , 2015, 1, 842.	7.1	0
250	Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: A good thing?. <i>European Journal of Cancer</i> , 2015, 51, 2272-2274.	2.8	10
251	Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 379-386.	2.2	1
252	Hard-Wired Bias. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1171-1175.	3.0	35

#	ARTICLE	IF	CITATIONS
253	Multiplying therapies and reducing toxicity in metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1014-1018.	3.4	9
254	Characteristics of Exceptional or Super Responders to Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1639-1649.	3.0	34
255	Distinctive clinical characteristics of malignant mesothelioma in young patients. <i>Oncotarget</i> , 2015, 6, 16766-16773.	1.8	42
256	But how many people died? Health outcomes in perspective. <i>Cleveland Clinic Journal of Medicine</i> , 2015, 82, 146-150.	1.3	8
257	Disease Specific Productivity of American Cancer Hospitals. <i>PLoS ONE</i> , 2015, 10, e0121233.	2.5	0
258	US News and World Report Cancer Hospital Rankings: Do They Reflect Measures of Research Productivity?. <i>PLoS ONE</i> , 2014, 9, e107803.	2.5	33
259	Comparative Effectiveness Questions in Oncology. <i>New England Journal of Medicine</i> , 2014, 370, 1478-1481.	27.0	39
260	Modern Drug Development. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2619.	7.4	5
261	Further Thoughts on Why There Are Good Data Supporting the Inferior Vena Cava Filter. <i>JAMA Internal Medicine</i> , 2014, 174, 164.	5.1	0
262	The Withdrawal of Drugs for Commercial Reasons. <i>JAMA Internal Medicine</i> , 2014, 174, 1887.	5.1	36
263	It Is Time to Stop Screening for Prostate Cancer. <i>JAMA Internal Medicine</i> , 2014, 174, 1841.	5.1	2
264	The Accelerated Approval of Oncologic Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 353.	7.4	51
265	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e15.	1.5	0
266	Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices. <i>Implementation Science</i> , 2014, 9, 1.	6.9	486
267	Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 521-524.	2.5	2
268	Long-term Effects of the 2003 ACGME Resident Duty Hour Reform on Hospital Mortality. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1023-1025.	3.0	1
269	The Peltzman effect and compensatory markers in medicine. <i>Healthcare</i> , 2014, 2, 170-172.	1.3	13
270	Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 1620-1629.	1.6	60

#	ARTICLE	IF	CITATIONS
271	Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesn't?. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1353-1357.	2.5	0
272	Does the Declining Lethality of Gunshot Injuries Mask a Rising Epidemic of Gun Violence in the United States?. Journal of General Internal Medicine, 2014, 29, 1065-1069.	2.6	32
273	The Declining Demand for Hospital Care as a Rationale for Duty Hour Reform. Journal of General Internal Medicine, 2014, 29, 1400-1403.	2.6	3
274	Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials?. Journal of Clinical Epidemiology, 2014, 67, 361-363.	5.0	12
275	Regarding Empiricism and Rationalism in Medicine and 2 Medical Worldviews. Mayo Clinic Proceedings, 2014, 89, 137.	3.0	3
276	Observational Studies Cannot Justify the Inferior Vena Cava Filter. American Journal of Medicine, 2014, 127, e15.	1.5	2
277	The misguided ethics of crossover trials. Contemporary Clinical Trials, 2014, 37, 167-169.	1.8	33
278	The Reply. American Journal of Medicine, 2014, 127, e21.	1.5	3
279	Statins, Primary Prevention, and Overall Mortality. Annals of Internal Medicine, 2014, 160, 867.	3.9	5
280	Rebuttal From Dr Rho et al. Chest, 2014, 145, 943-944.	0.8	0
281	Counterpoint: Were Industry-Sponsored Roflumilast Trials Appropriate? No. Chest, 2014, 145, 939-942.	0.8	6
282	Media Coverage of Medical Journals: Do the Best Articles Make the News?. PLoS ONE, 2014, 9, e85355.	2.5	44
283	Can a Resident's Publication Record Predict Fellowship Publications?. PLoS ONE, 2014, 9, e90140.	2.5	10
284	The Inferior Vena Cava Filter. JAMA Internal Medicine, 2013, 173, 493.	5.1	46
285	Open Issues with Open Access Publication. American Journal of Medicine, 2013, 126, 563-564.	1.5	12
286	Duty Hour Reform in a Shifting Medical Landscape. Journal of General Internal Medicine, 2013, 28, 1238-1240.	2.6	6
287	Treatment of Moderate to Severe Hidradenitis Suppurativa. Annals of Internal Medicine, 2013, 159, 72.	3.9	3
288	In reply "Reversal of Medical Practices. Mayo Clinic Proceedings, 2013, 88, 1183-1184.	3.0	3

#	ARTICLE	IF	CITATIONS
289	The Reply. American Journal of Medicine, 2013, 126, e45.	1.5	0
290	Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. Journal of Clinical Epidemiology, 2013, 66, 361-366.e4.	5.0	64
291	Handheld Ultrasounds: Pocket Sized, but Pocket Ready?. American Journal of Medicine, 2013, 126, 845-846.	1.5	8
292	A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices. Mayo Clinic Proceedings, 2013, 88, 790-798.	3.0	300
293	Why Randomized Controlled Trials Are Needed to Accept New Practices: 2 Medical Worldviews. Mayo Clinic Proceedings, 2013, 88, 1046-1050.	3.0	14
294	Prespecified Falsification End Points. JAMA - Journal of the American Medical Association, 2013, 309, 241.	7.4	204
295	Taking care of sick patients. Cmaj, 2013, 185, 1008-1008.	2.0	0
296	Falsification End Points for Observational Studies—Reply. JAMA - Journal of the American Medical Association, 2013, 309, 1769.	7.4	2
297	Why resident physicians stay late. Cmaj, 2013, 185, 1184-1184.	2.0	0
298	Routine Noninvasive Testing and Highly Sensitive Troponin Immunoassays—Reply. JAMA Internal Medicine, 2013, 173, 834.	5.1	0
299	The Inferior Vena Cava Filter—Reply. JAMA Internal Medicine, 2013, 173, 1754.	5.1	0
300	Characteristics of Cluster Randomized Trials: Are They Living Up to the Randomized Trial?. JAMA Internal Medicine, 2013, 173, 313.	5.1	7
301	Firearm Legislation and Gun-Related Fatalities. JAMA Internal Medicine, 2013, 173, 2011.	5.1	1
302	Evaluating Health System Processes With Randomized Controlled Trials. JAMA Internal Medicine, 2013, 173, 1279.	5.1	7
303	Double-Crossed: Why Crossover in Clinical Trials May Be Distorting Medical Science. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 625-627.	4.9	13
304	The overdiagnosis of pneumonia. Cleveland Clinic Journal of Medicine, 2013, 80, 616-618.	1.3	5
305	Dense breasts and legislating medicine. Cleveland Clinic Journal of Medicine, 2013, 80, 768-770.	1.3	5
306	Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more. Annals of Gastroenterology, 2013, 26, 277-278.	0.6	3

#	ARTICLE	IF	CITATIONS
307	Powering cancer screening for overall mortality. <i>Ecancermedalscience</i> , 2013, 7, ed27.	1.1	1
308	The Diagnosis and Treatment of Pulmonary Embolism. <i>Archives of Internal Medicine</i> , 2012, 172, 955-8.	3.8	35
309	A medical burden of proof: Towards a new ethic. <i>BioSocieties</i> , 2012, 7, 72-87.	1.3	20
310	Raise the Bar Even Higher for Primary Prevention Interventionsâ€”Reply. <i>Archives of Internal Medicine</i> , 2012, 172, 1352.	3.8	0
311	Cardiovascular Primary Prevention. <i>Archives of Internal Medicine</i> , 2012, 172, 656.	3.8	13
312	Freedom to Innovate: The Perils of Centralized Medical Researchâ€”Reply. <i>Archives of Internal Medicine</i> , 2012, 172, 1692.	3.8	0
313	The facts are the facts. <i>Cmaj</i> , 2012, 184, 2029-2030.	2.0	0
314	An Unmeasured Harm of Screening. <i>Archives of Internal Medicine</i> , 2012, 172, 1442.	3.8	4
315	Chest Pain in the Emergency Department. <i>Archives of Internal Medicine</i> , 2012, 172, 1506.	3.8	44
316	Publication Trends Among Internal Medicine Residents and Graduates. <i>American Journal of Medicine</i> , 2012, 125, 939-944.	1.5	13
317	Reversals of Established Medical Practices. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 37.	7.4	171
318	The apples and oranges of cost-effectiveness. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 377-379.	1.3	1
319	The apples and oranges of cost-effectiveness: A rejoinder. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 610-611.	1.3	0
320	Lacking the Incentive to Cure? Recurring <i>Clostridium difficile</i> Diarrhea and Our Reluctance to Use Fecal Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 379-380.	2.2	9
321	<i>Clostridium difficile</i> Diarrhea and Fecal Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 742-743.	2.2	10
322	Caution Needed When Predicting Problem Residents. <i>Academic Medicine</i> , 2011, 86, 2.	1.6	2
323	Steroids in infection: an old wives' tale. <i>Cmaj</i> , 2011, 183, 83-83.	2.0	1
324	The Frequency of Medical Reversal. <i>Archives of Internal Medicine</i> , 2011, 171, 1675.	3.8	114

#	ARTICLE	IF	CITATIONS
325	The Cardiovascular Biomarker Conundrum. JAMA - Journal of the American Medical Association, 2011, 306, 2151-2.	7.4	13
326	Perspective: Why There Must Be a Meditative Medicine. Alternative and Complementary Therapies, 2011, 17, 274-278.	0.1	0
327	Are We Treating Professionalism Professionally? Medical School Behavior as Predictors of Future Outcomes. Teaching and Learning in Medicine, 2011, 23, 337-341.	2.1	16
328	Reclaiming the morbidity and mortality conference: between Codman and Kundera. Medical Humanities, 2010, 36, 108-111.	1.2	20
329	Perspective: Beyond Storytelling in Medicine: An Encounter-Based Curriculum. Academic Medicine, 2010, 85, 794-798.	1.6	8
330	Baseline event rate, the Concorde fallacy, and the topography of cardiac risk. Medical Hypotheses, 2010, 75, 639-641.	1.5	1
331	Why Is Research in Early-Stage Cancer Research so Low? A Re-Assessment of Budish, Roin and Williams (2015). SSRN Electronic Journal, 0, , .	0.4	0